Iran turmoil missed Cosmos, while its U.S. collagen launch targets $12M – Stock Titan

CoreWeave Announces Multi-Year Agreement With Anthropic
SMX and CETI Set Industry Standard for Sustainable Ready-to-Wear
Erayak Announces Strategic Evolution into U.S.-Centric Energy Sol…
Roblox Announces Roblox Plus, a New Subscription Plan Offering Ex…
Allogene Therapeutics to Announce Interim Futility Analysis Data …
Venture Global Announces Closing of $1.75 Billion Senior Secured …
CoreWeave Announces Multi-Year Agreement With Anthropic
SMX and CETI Set Industry Standard for Sustainable Ready-to-Wear
Erayak Announces Strategic Evolution into U.S.-Centric Energy Sol…
Roblox Announces Roblox Plus, a New Subscription Plan Offering Ex…
Allogene Therapeutics to Announce Interim Futility Analysis Data …
Venture Global Announces Closing of $1.75 Billion Senior Secured …
Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.
The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.
COSM is down 3.33% while several peers like SNYR (-7.67%), ZYXI (-37.34%), and EDAP (-5.62%) are also lower, but no peers appeared in the momentum scanner, pointing to stock-specific trading rather than a defined sector rotation.
Recent crypto-tag news has often been positive operationally but produced mixed price reactions, with both gains and notable pullbacks.
Over the last few months, COSM has issued multiple crypto-tagged updates, from U.S. product launches and clinical validation to treasury crypto purchases and asset-valuation highlights. Price reactions have been modest, with several positive announcements (Liv18 launch, C‑Scrub EN 12791 success, Bitcoin purchases) seeing small gains, while valuation and growth updates around real estate and U.S. expansion sometimes coincided with declines. Today’s update on record revenue and NOOR expansion fits this stream of growth-focused communications.
Recent crypto-tagged COSM news saw an average move of -0.81%, suggesting that even upbeat growth and asset updates have not typically driven large sustained swings.
Crypto-tagged releases show a progression from highlighting asset values and crypto treasury strategy to expanding U.S. product lines and clinical validation, framing today’s NOOR and revenue update as a continuation of this growth-focused narrative.
COSM has an effective Form S-3 shelf filed on Nov 7, 2025, registering up to $200,000,000 in securities, including an at-the-market program of up to $100,000,000 of common stock. The filing states net proceeds are intended primarily for acquisition of crypto assets as treasury holdings and for general corporate purposes.
This announcement underscores that geopolitical tensions in the Middle East have had negligible operational impact while COSM reports record Q3 2025 revenue of $17.1 million, gross margin of 15.21%, and stronger cash of $4.63 million. Management reiterates expectations for NOOR U.S. revenue to exceed $12 million at roughly 75% gross margins over 12 months. Historically, similar crypto‑tagged updates generated modest and mixed price moves, so investors may focus on forthcoming FY 2025 results and execution of the U.S. expansion plan.
AI-generated analysis. Not financial advice.
CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company’s operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.
Geopolitical Resilience Underpins Global Platform
Cosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions. The conflict in the Middle East and recent geopolitical developments have had a negligible impact on the Company’s operations. Management expects strong growth momentum to continue as the Company advances toward sustained profitability.
Record Revenue Momentum Continues
The Company’s most recently reported quarter, Q3 2025, marked a new all-time high, with revenue reaching $17.1 million, a 38% increase year-over-year. Gross profit more than doubled, increasing 116% to $2.6 million, with a record gross margin of 15.21%, while Adjusted EBITDA improved 74%. Cash position strengthened to $4.63 million, up from $0.66 million at the end of Q2 2025.
This record-setting momentum has continued into subsequent periods. More detailed financial information will be provided in conjunction with the Company’s fourth quarter and full-year 2025 results, expected shortly.
NOOR U.S. Expansion Accelerating
Sales of Sky Premium Life NOOR collagen in the United States are already underway, with the product manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.
The Company anticipates gross margins of approximately 75% from its U.S. operations, with NOOR collagen alone projected to generate more than $12 million in revenue within the next 12 months, positioned to benefit from the U.S. nutraceuticals market, valued at $163.7 billion in 2024 and projected to grow at a 6.2% CAGR through 2030, according to Grand View Research.
Greg Siokas, CEO of Cosmos Health, stated: “Our business has never been stronger. Q3 2025 marked our highest revenue, gross profit, and gross margin in the Company’s history – and that momentum has continued. Our geographically diversified platform insulates us from regional disruptions, while the accelerating U.S. expansion of Sky Premium Life NOOR represents a transformational growth opportunity. We expect NOOR U.S. revenues to exceed $12 million within the next 12 months, at gross margins of approximately 75%, and we look forward to providing the full picture with our forthcoming 10-K filing.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life^®, Mediterranation^®, bio-bebe^®, C-Sept^® and C-Scrub^®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
Continue reading with these related stories
© 2020-2026 StockTitan.net – Your Edge is Information
Information only — not investment advice.

source